Stocks · News reference
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Voyager Therapeutics (NASDAQ:VYGR) with a Buy and maintains $25 price target.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.48) by 16.67 percent. This is a 29.82 percent increase over losses of $(0.57) per share
Read original at benzingaFiled: 2026-07-13 AccNo: 0001104659-26-082906 Size: 197 KB Item 8.01: Other Events
Read original at edgar- Data presented as Developing Topics poster at AAIC 2026 -LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to leveraging genetics to treat
Read original at benzinga